(Hua et al., Shaw et al., Yip et al.) SKOV3ip.1 (Yu et al.) SKOV3x (Shao et al.) SKOV3TR (Landen et al.)
S:III, Tumor tissue
(Giannakakou et al.)
S:IIIC, G:3, Tumor tissue. P53 mutation. Very aggressive, 42 yr old pt. survived only 3 months.
(Provencher et al.)
S:III, G:3, Tumor tissue. 42 yr old pt. P53 wt.
(Provencher et al.)
(Hill et al.)
(Cheung et al.)
S:III, Ascites/ Tumor tissue
Cyclophosphamide, Adriamycin, Cisplatin, Taxol
(Fuchtner et al.)
Serous, mutated BRCA1 exon 11
(DelloRusso et al.)
a Stage, S; Grade, G; Tumor, cell line derived from solid tumor tissue; Ascites, cell line derived from ascetic fluid.
b Treatments were done before initial derivation of cell line. *Sub-lines of A2780. †Sub-lines of Hey. ‡Sub-lines of 2008.
c Sequencing information at http://www.broadinstitute.org/ccle/home and published by Barretina and colleagues (Barretina et al.). This website contains sequencing information on 50 ovarian cancer cell lines
d Sequencing information for the NCI 60 celllines is available at http://discover.nci.nih.gov/cellminer/home.do References
1. Afzal, S. et al., 1985, MTI-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts: Human Pathology, v. 29, p. 155-180.
2. Ahmed, N. et al., 2002, Overexpression of avb6 integrin in serous epithelial ovarian cancer regulates extracellular matrix degradation via the plasminogen activation cascade: Carcinogenesis, v. 23, no. 2, p. 237-244.
3. Alama, A. et al., 1996, Establishment and characterization if three new cell lines derived from the ascites of human ovarian carcinomas: Gynecologic Oncology, v. 62, p. 82-88.
4. Andrews, P. et al., 1985, Differential potentiation of alkylating and platinating agent cytotoxicity in human ovarian carcinoma cells by gluthatione depletion: Cancer Research, v. 45, p. 6250-6253.
5. Barretina, J. et al., 2012, The cancer cell line encyclopedia enables predictive modeling of anticancer drug sensitivity: Nature, v. 483, p. 603-607.
6. Benard, J. et al., 1985, Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice: Cancer Research, v. 45, p. 4970-4979.
7. Boocock, C. A. et al., 1995, Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma: Journal of the National Cancer Institute, v. 87, no. 7, p. 506-516.
8. Buick, R. N. et al., 1985, Comparative properties of five human ovarian adenocarcinoma cell lines: Cancer Research, v. 45, p. 3668-3676.
9. Burbridge, M. et al., 1999, Biological and pharmacological characterisation of three models of human ovarian carcinoma established in nude mice: Use of the CA125 tumour marker to predict antitumour activity: International Journal of Oncology, v. 15, p. 1155-1162.
10. Cheung, H. W. et al., 2011, Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer: Proceedings of the National Academy of Sciences USA, v. 108, no. 30, p. 12372-12377.
11. DelloRusso, C. et al., 2013, Functional characterization of a novel BRCA1-null ovarian cancer cell lilne in response to ionizing radiation: Molecular Cancer Research, v. 5, p. 35-45.
12. Freedman, R. S. et al., 1978, Characterization of an ovarian carcinoma cell line: Cancer, v. 42, no. 5, p. 2352-2359.
13. Fuchtner, C. et al., 1993, Characterization of a human ovarian carcinoma cell lines: Gynecologic Oncology, v. 48, no. 2, p. 203-209.
14. Giannakakou, P. et al., 1997, Pacliaxel-resistant human ovarian cancer cells have mutant b-tubulins that exhibit impaired paclitaxel-driven polymerization: Journal of Biological Chemistry, v. 272, no. 27, p. 17118-17125.
15. Gorai, I. et al., 1995, Establishment of two human ovarian clear cell adenocarcinoma lines from metastatic lesions with fifferent properties: Gynecologic Oncology, v. 57, p. 33-46.
16. Green, J. A. et al., 1984, Potentiation of melphalan cytotoxicity in human ovarian cancer cell lines by gluthatione depletion: Cancer Research, v. 44, p. 5427-5431.
17. Greenaway, J. et al., 2008, Epithelial-stromal interaction increases cell proliferation, survival and tumorigenicity in a mouse model of human epithelial ovarian cancer: Gynecologic Oncology, v. 108, p. 385-394.
18. Hamilton, T. C. et al., 1983, Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors: Cancer Research, v. 43, p. 5379-5389.
19. Hill, B. T. et al., 1987, Establishment and characterization of three new human ovarian carcinoma cell lines and initial evaluation of their potential in experimental chemotherapy studies: International Journal of Cancer, v. 39, p. 219-225.
20. Holzel, F. et al., 1983, Cell lines derived from human ovarian carcinomas: Growth stimulation by gonadotropic and steroid hormones: Journal of the National Cancer Institute, v. 70, p. 839-845.
21. Hua, W. et al., 1995, SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth resistant to estrogens and antiestrogens: J Steroid Biochem Molec Biol, v. 55, p. 279-289.
22. Introna, M., and R. C. Bast, 1985, Epithelial ovarian carcinoma: Cell lines and antigenic tumor markers., in JMA Whitehouse and C.Williams ed., Cancer of the female reproductive system: John Wiley and Sons, p. 153-180.
23. Karlan, B. Y. et al., 1994, Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells: Gynecologic Oncology, v. 53, p. 70-77.
24. Kaur, S. et al., 2009, b3-integrin expression on tumor cells inhibits tumor progression, reduces metastasis, and is associated with a favorable prognosis in patients with ovarian cancer: American Journal of Pathology, v. 175, no. 5, p. 2184-2196.
25. Landen, C. N. et al., 2010, Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer: Molecular Cancer Therapeutics, v. 9, no. 12, p. 3186-3199.
26. Langdon, S. P. et al., 1988, Characterization and properties of 9 human ovarian carcinoma cell lines: Cancer Research, v. 48, p. 6166-6172.
27. Lau, D. H. M. et al., 1991, Multifactorial mechanisms associated with broad cross-resistance of ovarian carcinoma cells selected by cyanomorpholino doxorubicin: Cancer Research, v. 51, p. 5181-5187.
28. Pirker, R. et al., 1985, Characterization of immunotoxins active against ovarian cancer cell lines: Immunotox agasinst ovarian cancer, v. 76, p. 1261-1267.
29. Provencher, D. M. et al., 200, Characterization of four novel epithelial ovarian cancer cell lines: In Vitro Cell Dev Biol Anim, v. 36, no. 6, p. 357-361.
30. Roby, K. F. et al., 2000, Development of a syngeneic mouse model for events related to ovarian cancer: Carcinogenesis, v. 21, no. 4, p. 585-591.
31. Rodriguez, G. C. et al., 1999, Epidermal growth factor receptor expression in normal ovarian epithelium and ovarian cancer: American Journal of Obstetrics and Gynecology, v. 164, no. 3, p. 745-750.
32. Sakayori, M. et al., 1990, Biological properties of two newly established cell lines (RMUG-S, RMUG-L) from a human ovarian mucinous cystadenocarcinoma: Human Cell, v. 3, p. 52-56.
33. Shao, M. et al., 2009, Epithelial-to-mesenchymal transition and ovarian tumor progression induced by tissue transglutaminase: Cancer Research, v. 69, no. 24, p. 9192-9201.
34. Shaw, T. J. et al., 2006, Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer: Molecular Therapy, v. 10, p. 1032-1042.
35. Steinmeyer, C. et al., 2003, The expression of hCG receptor mRNA in four human ovarian cancer cell lines varies considerably under different experimental conditions: Tumour Biol, v. 24, p. 13-22.
36. Taniguchi, T. et al., 2003, Disruption of the fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors: Nature Medicine, v. 9, p. 568-574.
37. Urzua, U. et al., 2010, Microarray proteomic analysis discriminates tumorigenic mouse ovarian surface epithelial cells of divergent aggressive potential: Molecular Biosystems, v. 6, no. 12, p. 2521-2528.
38. van der Berg-Baker, C. A. et al., 1993, Establishment and characterization of 7 ovarian carcinoma cell lines and one granulosa tumor cell line: Growth features and cytogenetics: International Journal of Cancer, v. 53, no. 4, p. 613-620.
39. Wilson, A. P. et al., 1996, Characterisation of seven human ovarian tumour cell lines: British Journal of Cancer, v. 74, p. 722-727.
40. Yip, K. W. et al., 2006, Potential use of alexidine dihydrochloride as an apoptosis-promoting anticancer agent: Molecular Cancer Therapeutics, v. 5, no. 9, p. 2234-2240.
41. Yu, D. et al., 1992, Enhanced c-erb B-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A: Cancer Research, v. 53, p. 891-898.